Moira Hagen

Moira Hagen has a strong background in the pharmaceutical industry and extensive experience as a Medical Science Liaison. Moira began their career at the University of Colorado Health Sciences Center, where they worked as an Instructor from 2004 to 2007. During this time, they focused on researching new therapeutic targets for HHV-8, particularly in relation to Kaposi's Sarcoma and HIV co-infections.

After their time at the University of Colorado, Hagen joined Bristol-Myers Squibb in 2007 as a Medical Science Liaison. In this role, they critically evaluated clinical and disease state data, disseminating this information to HIV and HBV key opinion leaders and healthcare providers. Moira also followed up with clinical trial investigators, conducted formal presentations, and collaborated with medical matrix teams on various projects.

In 2010, Hagen moved to Vertex Pharmaceuticals, where they continued their work as a Medical Science Liaison. Their main focus was on educating hepatology and gastrointestinal key opinion leaders, as well as community healthcare providers, on HCV disease state, treatment, side effect management, and the evolving landscape of HCV. Moira also worked with community organizations to support their initiatives and update them on new data and developments in the field.

In 2014, Hagen joined AbbVie as a Medical Science Liaison. Moira focused on educating and engaging external experts in dialogue about the AbbVie Hepatitis C program, preparing them for the launch of a new regimen. Moira developed new relationships with external experts and effectively explained relevant data and concepts to healthcare providers of all levels.

Most recently, Hagen worked at Intercept Pharmaceuticals as a Medical Science Liaison starting in 2015. Their primary focus was educating hepatology and gastroenterology healthcare professionals about the FXR agonist obeticholic acid, specifically its mechanism of action and safety/efficacy profile in the rare disease Primary Biliary Cholangitis. Moira also conducted NASH disease state awareness programs and provided reactively presentations of new data in NASH. Additionally, they supported clinical trials by recommending sites and educating principal investigators on the supporting data for the trial.

Overall, Hagen's work experience demonstrates their expertise in medical science liaison roles within the pharmaceutical industry and their ability to effectively communicate complex data and concepts to healthcare professionals.

Moira Hagen holds a PhD in Biochemistry from the University of Colorado Boulder. The specific start and end years of their education are not provided.